Drug Antitrust

A federal antitrust complaint claims Bausch Health Cos., Salix Pharmaceuticals, et al. increased prices for the diabetes prescription drug Glumetza by up to <a href="http://www.courthousenews.com/wp-content/uploads/2019/08/Drug-antitrust.pdf"><strong>50 times the fair market price</strong></a>: as high as $3,000 for a month’s supply.

SAN FRANCISCO — A federal antitrust complaint claims Bausch Health Cos., Salix Pharmaceuticals and others increased prices for the diabetes prescription drug Glumetza by up to 50 times the fair market price: as high as $3,000 for a month’s supply.

Categories / Business, Health

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.